Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.42 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.42 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15849107 | 0.92 | MAPT (0.44) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL1110657 | 0.90 | SRPK1 (0.55) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL1110655 | 0.90 | SRPK1 (0.55) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL1110656 | 0.90 | SRPK1 (0.55) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL20117642 | 0.89 | MEN1 (0.45) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL21322827 | 0.89 | MEN1 (0.45) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL15277918 | 0.89 | KDR (0.55) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL15277927 | 0.89 | KDR (0.55) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL21322828 | 0.89 | KDR (0.55) | LMNAKDRSRPK2SRPK1SRPK3 | |
| SCHEMBL15277956 | 0.84 | KDR (0.44) | LMNAKDRSRPK2SRPK1SRPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200188382-A1 | PHARMACEUTICAL COMPOSITION FOR INDUCING PROGRAMMED CELL DEATH IN CANCER CELLS | KYOTO UNIVERSITY (JP) | 2020-06-18 | — | — | US | disclosed |
| WO-2018079855-A1 | PHARMACEUTICAL COMPOSITION FOR INDUCING PROGRAMMED CELL DEATH IN CANCER CELLS | 国立大学法人京都大学 | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200188382-A1 | PHARMACEUTICAL COMPOSITION FOR INDUCING PROGRAMMED CELL DEATH IN CANCER CELLS | CASP3, BAX, BAD | LMNA 1177/4885KDR 3850/4885SRPK2 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.